Reason for request
- Re-assessment of the improvement in actual benefit at the applicant’s
Clinical Benefit
Clinical Added Value
| minor |
Au regard des nouvelles données disponibles, l’ipilimumab (YERVOY) conserve son amélioration du service médical rendu mineure (ASMR IV) dans la stratégie thérapeutique. |
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
rt9htWLhCEByXyP8
